New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:01 EDTAMGNXencor initiates Phase 1b/2a trial of XmAb5871
Xencor announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb5871 in patients with moderate to severe rheumatoid arthritis.  XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone payment of an undisclosed amount to Xencor from Amgen. XmAb5871 is a humanized and Fc engineered monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by co-engaging CD19 and CD32b. Amgen and Xencor entered into an option and co-development agreement for XmAb5871 in January 2011. Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time and is eligible for early development milestone payments.
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:02 EDTAMGNAmgen management to meet with UBS
Subscribe for More Information
November 19, 2014
07:09 EDTAMGNJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
16:02 EDTAMGNAmgen presents long-term data on safety, efficacy of evolocumab
Subscribe for More Information
09:23 EDTAMGNAmgen to host conference call
Management discusses Amgen's cardiovascular program, as well as the evolocumab data presented at the American Heart Association (AHA) Scientific Sessions 2014, on a conference call to be held on November 18 at 7 pm. Webcast Link
07:03 EDTAMGNAmgen management to meet with UBS
Meeting to be held in Zurich on November 18 hosted by UBS.
November 14, 2014
16:58 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
09:38 EDTAMGNJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
09:37 EDTAMGNJANA reports new stakes in McDonald's, AECOM, Amgen
Subscribe for More Information
07:14 EDTAMGNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 11, 2014
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
November 10, 2014
15:54 EDTAMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use